

# Suriname

## Tuberculosis profile

Population 2016

<1 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.011 (0.011–0.012)	2 (1.9–2.1)
Mortality (HIV+TB only)	<0.01 (<0.01–0.01)	1.4 (1–1.8)
Incidence (includes HIV+TB)	0.14 (0.11–0.18)	26 (20–32)
Incidence (HIV+TB only)	0.036 (0.028–0.046)	6.5 (5–8.3)
Incidence (MDR/RR-TB)**	0.011 (<0.01–0.019)	1.9 (0.44–3.4)

Estimated TB incidence by age and sex (thousands)\*, 2016

	0-14 years	> 14 years	Total
Females	0.01 (<0.01–0.013)	0.043 (0.032–0.054)	0.053 (0.04–0.067)
Males	0.011 (<0.01–0.014)	0.078 (0.059–0.098)	0.089 (0.067–0.11)
Total	0.022 (0.016–0.027)	0.12 (0.091–0.15)	0.14 (0.11–0.18)

TB case notifications, 2016

Total cases notified	116
Total new and relapse	114
- % tested with rapid diagnostics at time of diagnosis	66%
- % with known HIV status	94%
- % pulmonary	85%
- % bacteriologically confirmed among pulmonary	82%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2016	80% (63–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.14 (0.1–0.18)

TB/HIV care in new and relapse TB patients, 2016

	Number	(%)
Patients with known HIV-status who are HIV-positive	25	23%
- on antiretroviral therapy	14	56%

Drug-resistant TB care, 2016	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			6 (0–11)
Estimated % of TB cases with MDR/RR-TB	6.1% (1.7–15)	0% (0–41)	
% notified tested for rifampicin resistance	63%	67%	75
MDR/RR-TB cases tested for resistance to second-line drugs			0
Laboratory-confirmed cases		MDR/RR-TB: 4, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 0, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2015	76%	140
Previously treated cases, excluding relapse, registered in 2015	29%	7
HIV-positive TB cases registered in 2015	58%	36
MDR/RR-TB cases started on second-line treatment in 2014		0
XDR-TB cases started on second-line treatment in 2014		0

TB preventive treatment, 2016

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2017

National TB budget (US\$ millions)	1.6
Funding source: 25% domestic, 32% international, 43% unfunded	


\* Ranges represent uncertainty intervals

\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history


\*\*\*\* Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)



— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016



Treatment success rate (%)



— New and relapse  
— Retreatment, excluding relapse  
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)

